Altimmune (ALT) Net Equity Issued and Repurchased (2011 - 2026)

Altimmune (ALT) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $34.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 1.58% year-over-year to $34.2 million; the TTM figure through Mar 2026 stood at $173.2 million (up 60.36% YoY), while the FY2025 annual figure was $173.7 million, up 1638.37% from the prior year.
• Net Equity Issued and Repurchased retreated to $34.2 million in Q1 2026 per ALT's latest filing, from $61.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $72.7 million in Q4 2023 and bottomed at $510000.0 in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $33.7 million across 4 years, with a median of $34.5 million in 2025.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased climbed 17.43% — and 2023, when it plunged 98.4%.
• Altimmune's Net Equity Issued and Repurchased stood at $31.8 million in 2022, then jumped by 128.53% to $72.7 million in 2023, then fell by 15.25% to $61.6 million in 2025, then tumbled by 44.52% to $34.2 million in 2026.
• Business Quant data shows ALT's Net Equity Issued and Repurchased at $34.2 million in Q1 2026, $61.6 million in Q4 2025, and $39.5 million in Q3 2025.